Echo IQ (EIQ) Q1 2025 TU earnings summary

Strategic and operational highlights

• Entered a strategic integration partnership with ScImage Inc. to incorporate EchoSolv-AS into the PICOM365 Cloud platform, targeting key US cardiology practices and hospitals by year-end 2024.

• Achieved positive results in two clinical studies, with AI technology identifying 86% of heart failure patients without human review and 97% with AI-aided human review.

• Featured in two late-breaking science presentations at ESC Congress 2024, enhancing global exposure and validating innovation in cardiovascular diagnostics.

• Raised $7.1 million in an oversubscribed placement to fund commercialization and product development.

• Secured FDA 510(k) clearance for EchoSolv-AS, enabling US market entry and commercialization.

Financial and corporate position

• Cash and cash equivalents stood at $7.118 million as of 30 September 2024, with steady operational cash use.

• Net cash used in operating activities for the quarter was $1.647 million, with an estimated 4.3 quarters of funding available.

• $6.655 million was raised after costs during the quarter, primarily for commercialization and development.

• Payments to related parties totaled $138,000 for director and related costs.

Regulatory and commercial progress

• FDA clearance for EchoSolv-AS positions the company to convert ongoing negotiations with hospital groups, device manufacturers, and pharmaceutical companies into material agreements.

• Focused on securing CMS reimbursement codes to support broader US adoption and financial incentives for EchoSolv-AS.

• Advancing regulatory strategy for heart failure AI solution, with a pre-submission meeting planned with the FDA.